Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Lung Cancer

    U.S. Senate Designates November as National Lung Cancer Awareness Month
    Lung Cancer

    U.S. Senate Designates November as National Lung Cancer Awareness Month

    The U.S. Senate unanimously passed a resolution designating November as National Lung Cancer Awareness Month and supporting early detection of lung cancer, a crucial awareness with smoking on the rise among young adults.

    January 07, 2021
    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) as adjuvant therapy after tumor resection for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. 

    December 21, 2020
    ONS Supports Bipartisan  Resolution  to Recognize November as National Lung Cancer Awareness Month
    Lung Cancer

    ONS Supports Bipartisan  Resolution  to Recognize November as National Lung Cancer Awareness Month

    Lung cancer knows no state boundary or political ideology. But it can bring the two sides together, like it did when U.S. Senators Tina Smith (D-MN), member of the Senate Health Committee, and Marco Rubio (R-FL) introduced a resolution to recognize November as National Lung Cancer Awareness Month. The resolution, which ONS supports, promotes the importance of and need to improve lung cancer early detection.

    December 14, 2020
    Smoking Initiation Declines in Teens, Rises in Young Adults
    Lung Cancer

    Smoking Initiation Declines in Teens, Rises in Young Adults

    The average age at which cigarette users start to smoke regularly has risen. Although the figures dropped from 45% of adults smoking cigarettes in the 1960s to 14% today, and teen smoking declined to 2.4% by 2019, results of a recent study show an upward trend of underage tobacco use in young adults.  

    December 01, 2020
    Oncology Drug Reference Sheet: Selpercatinib
    Clinical practice

    Oncology Drug Reference Sheet: Selpercatinib

    In May 2020, the U.S. Food and Drug Administration gave accelerated approval for selpercatinib (Retevmo®) to treat RET-altered non-small cell lung cancer or thyroid cancer based on overall response rate and duration of response. Selpercatinib fights cancer by impeding RET protein activity. The determining clinical trial results demonstrated that it reduced tumor size in more than 50% of patients and was associated with fewer adverse reactions than other drugs that block the RET protein.

    November 24, 2020
    Resource Helps Explain the Potential Dangers of E-Cigarettes to Providers and Patients
    Lung Cancer

    Resource Helps Explain the Potential Dangers of E-Cigarettes to Providers and Patients

    E-cigarettes are dangerous and their risks outweigh any potential smoking-cessation benefits, the U.S. Government Accountability Office explained in a new two-page resource that analyzes the science and technology behind the devices.

    November 06, 2020
    Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship
    Lung Cancer

    Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship

    Lung cancer is the leading cause of cancer death in the United States, accounting for about one quarter of cancer deaths, and more than a quarter of million lung cancer diagnoses are projected in the United States for 2020. Lung cancer has various types, pathologies, and histologies, each with its own prognosis and treatment plan. Non-small cell lung cancer consists of about 80%–85% of lung cancer diagnoses.

    November 05, 2020
    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions

    On September 4, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pralsetinib (Gavreto™) for adult patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

    September 10, 2020
    Treating Mental Health May Improve Lung Cancer Survival
    Cancer research

    Treating Mental Health May Improve Lung Cancer Survival

    Patients with lung cancer who also had mental health disorders saw improved cancer-related outcomes when their mental illness was treated, according to findings from a study published in JAMA Oncology.

    September 02, 2020
    FDA Approves First Liquid Biopsy NGS Companion Diagnostic Test for NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Liquid Biopsy NGS Companion Diagnostic Test for NSCLC

    On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360 CDx assay as the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in patients with metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies in one diagnostic test to guide treatment decisions. 

    August 11, 2020
    Manage Immune-Related Adverse Events in Patients on Durvalumab
    Adverse events

    Manage Immune-Related Adverse Events in Patients on Durvalumab

    Durvalumab immunotherapy became a new standard of care for patients with stage III unresectable non-small cell lung cancer whose disease did not progress following two cycles of platinum-based chemoradiotherapy after its approval in February 2018, and in March 2020, its indication was expanded for use as first-line treatment in patients with extensive-stage small cell lung cancer as well. Key to keeping patients on immunotherapy treatment and giving them the best chance at long-term survival is effective management of immune-related adverse events.

    August 11, 2020
    NIH Study Links Cigarette Smoking to Higher Stroke Risk in African Americans
    Lung Cancer

    NIH Study Links Cigarette Smoking to Higher Stroke Risk in African Americans

    The disproportionate adverse health impact from smoking on African Americans is striking. Although oncology nurses are well aware of tobacco’s carcinogenic effects, they also need to understand the implications for comorbid conditions they may see in smokers with cancer. A recent study, through the National Institutes of Health (NIH), confirmed that African Americans have a 2.5 times higher incident of smoking-related strokes than those who never smoke.

    July 06, 2020
    Nurses Obliged to End Racism; Tobacco Industry's Manipulative Marketing
    Cancer healthcare advocacy

    Nurses Obliged to End Racism; Tobacco Industry's Manipulative Marketing

    Along with many other healthcare organizations, including ONS, last week the American Nurses Association (ANA) took a bold stand against racism, calling it a public health crisis. On June 12, 2020, ANA President Earnest Grant shared how racism is embedded in health care and what nurses should do to end it.

    June 22, 2020
    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression

    On May 18, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining ≥ 50% of tumor cells [TC] or PD-L1-stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area), with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. 

    May 19, 2020
    FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer

    On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥ 1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. 

    May 18, 2020
    FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions

    On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo™) for adult patients with metastatic, RET fusion–positive non-small cell lung cancer (NSCLC); adult and pediatric patients aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and adult and pediatric patients aged 12 or older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are refractory to radioactive iodine (if radioactive iodine is appropriate). This is the first drug approval for RET genetic alterations.

    May 12, 2020
    FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung Cancer

    On May 6, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib (Tabrecta™) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test. It is the first drug approval for this specific patient population and the first targeted therapy for the indication.

    May 07, 2020
    House Tells FDA to Ban E-Cigarettes During COVID-19
    COVID-19

    House Tells FDA to Ban E-Cigarettes During COVID-19

    On April 1, 2020, the U.S. House of Representatives Subcommittee on Economic and Consumer Policy asked the U.S. Food and Drug Administration (FDA) to clear the market of e-cigarettes because of the COVID-19 coronavirus pandemic. It was responding to FDA’s request to give e-cigarette manufacturers four additional months to submit applications to stay on the market before enforcing a ban.  

    April 28, 2020
    FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer

    On March 27, 2020, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). 

    March 30, 2020
    Smoking Rates Are Low, But Here’s How They Can Be Lower
    Lung Cancer

    Smoking Rates Are Low, But Here’s How They Can Be Lower

    Although U.S. smoking rates have hit an all-time low of 14%, 34 million American adults are still considered active smokers, according to the U.S. surgeon general’s January 2020 report on smoking cessation. It’s the first new report focused directly on smoking cessation from the surgeon general’s office in 30 years. 

    March 04, 2020
    Cancer Death Rates See Largest-Ever Single-Year Drop
    American Cancer Society (ACS)

    Cancer Death Rates See Largest-Ever Single-Year Drop

    Overall U.S. cancer mortality fell 2.2% from 2016 to 2017, the largest reduction for a single year, according to the American Cancer Society’s “Cancer Statistics, 2020,” published in CA: A Cancer Journal for Clinicians.

    February 26, 2020
    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer
    Treatments

    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer

    Pegilodecakin, an investigational, first-in-class drug currently in clinical trials, is demonstrating positive safety results and measurable responses when used in combination with pembrolizumab or nivolumab in patients with non-small cell lung cancer (NSCLC) or kidney cancer. The findings from the multicenter, phase IB study were published in Lancet Oncology.

    January 28, 2020
    FDA Approves Atezolizumab With Paclitaxel Protein-Bound and Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab With Paclitaxel Protein-Bound and Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations

    On December 3, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

    December 05, 2019
    CDC Promotes Lung Cancer Screening Awareness and Prevention
    Lung Cancer

    CDC Promotes Lung Cancer Screening Awareness and Prevention

    As the leading cause of cancer death in the United States, lung cancer is pervasive and deadly. But like many cancers, patients have a better chance at successful treatment outcomes and survival if caught early through screening and early detection efforts. Despite lung cancer being the second most diagnosed cancer for men and women, not all Americans are aware of its screening recommendations. To address the gap in awareness, the Centers for Disease Control and Prevention (CDC) is promoting a new public health campaign on the issue.

    November 21, 2019
    Biomarker-Based Screening Test May Find Lung Cancer at Earlier Stages
    Lung Cancer

    Biomarker-Based Screening Test May Find Lung Cancer at Earlier Stages

    A blood test evaluating several biomarkers was able to reduce the number of lung cancers detected at later stages, according to study results presented at the 2019 World Conference on Lung Cancer.

    November 13, 2019
    Model May Help Predict Lung Cancer Risk in Patients With Nodules
    Cancer risk factors

    Model May Help Predict Lung Cancer Risk in Patients With Nodules

    A risk-prediction model that combines patients’ health history with clinical characteristics of their lung nodules may help physicians determine which will develop into cancer, according to the results of a study published in Cancer Prevention Research.

    September 25, 2019
    Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer
    Treatments

    Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer

    The U.S. Food and Drug Administration (FDA) first approved atezolizumab (Tecentriq®) in 2016, but it received additional approvals when used in combination treatments for locally advanced or metastatic triple negative breast cancer (TNBC) and small cell lung cancer (SCLC) in March 2019.

    July 23, 2019
    Liquid Biopsy Equivalent to Tissue for NSCLC
    Lung Cancer

    Liquid Biopsy Equivalent to Tissue for NSCLC

    With faster and equally accurate results, liquid biopsy may be an option for identifying guideline-recommended targeted therapies for non-small cell lung cancer (NSCLC), according to findings presented at the 2019 American Association for Cancer Research Annual Meeting in Atlanta, GA. 

    May 08, 2019
    ONS Congress

    Nurses Are Critical to Increasing Awareness of Lung Cancer Screening

    Nurses, who are frequently on the front lines of communication with patients at high risk for lung cancer, can play a critical role in increasing awareness of the relatively new option to screen for this deadly condition, Lisa Carter-Harris, PhD, APRN, ANP-C, FAAN, of Memorial Sloan Kettering Cancer Center in New York, NY, said in the Victoria Mock New Investigator Presentation on Saturday, April 13, 2019, at the ONS 44th Annual Congress in Anaheim, CA.

    April 13, 2019
    FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer

    On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.

    March 19, 2019
    Which of the Following Leads to the Greatest Percentage of Superior Vena Cava Syndrome Cases?
    Lung Cancer

    Which of the Following Leads to the Greatest Percentage of Superior Vena Cava Syndrome Cases?

    Which of the Following Leads to the Greatest Percentage of Superior Vena Cava Syndrome Cases?           

    A. Small cell lung cancer

    B. Non-Hodgkin lymphoma

    C. Non-small cell lung cancer 

    D. Kaposi sarcoma                

    March 08, 2019
    Immunotherapy May Increase Risk for Hyperprogressive Lung Cancer
    Lung Cancer

    Immunotherapy May Increase Risk for Hyperprogressive Lung Cancer

    Some patients receiving checkpoint inhibitors for lung cancer may experience increased risk for hyperprogressive disease (HPD), according to results of a study reported in JAMA Oncology.

    December 26, 2018
    JADPRO Live

    Psychosocial Support May Reduce Stigma for Patients With Lung Cancer

    Because of the relationship between cigarette smoking and lung cancer, patients who receive a lung cancer diagnosis may feel judgment compared to patients with other cancer diagnoses, which could affect social interactions between family, caregivers, and healthcare professionals. Perceived lung cancer stigma can lead to depression, anxiety, poor self-esteem, guilt, shame, blame, poor social identity, and reduced social support. A recent study indicated that lung cancer stigma might be behind the low lung cancer screening rates among high-risk smokers.

    November 13, 2018
    FDA Approves Lorlatinib for Second, Third-Line Treatment of ALK-Positive Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lorlatinib for Second, Third-Line Treatment of ALK-Positive Metastatic NSCLC

    On November 2, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (Lorbrena) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

    November 05, 2018
    FDA Cracks Down on Vaping Pods Because of High Nicotine Levels in Young Users
    U.S. Food and Drug Administration (FDA)

    FDA Cracks Down on Vaping Pods Because of High Nicotine Levels in Young Users

    In September 2018, the U.S. Food and Drug Administration (FDA) issued more than 1,100 warning letters and fines to retailers and issued 131 fines for selling vaping pod products to minors. The agency also told manufacturers that the industry has 60 days to provide a plan to limit underage access to these products or face penalties.

    October 31, 2018
    First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer
    Treatments

    First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer

    Lung cancer is the second most common cancer in both men and women (after skin cancer) and is the leading cause of cancer death among both men and women. Histology has become an important determinant in choosing therapy for various types of cancer, including non-small cell lung cancer (NSCLC). Currently, biomarker testing is the standard of care in lung cancer; with biomarker testing, patients likely to respond to targeted therapy can be identified. As the number of targeted agents continues to increase, so does the demand for continued biomarker testing and adequate tumor tissue samples.

    September 14, 2018
    FDA Grants Nivolumab Accelerated Approval for Third-line Treatment of Metastatic SCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Nivolumab Accelerated Approval for Third-Line Treatment of Metastatic SCLC

    On August 16, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.

    August 20, 2018
    Which of the Following Patient Types Is Not Indicated for Lung Cancer Screening With Low-dose Helical Computed Tomography?
    Lung Cancer

    Which of the Following Patient Types Is Not Indicated for Lung Cancer Screening With Low-Dose Helical Computed Tomography?

    Which of the Following Patient Types Is Not Indicated for Lung Cancer Screening With Low-dose Helical Computed Tomography?

    A. Is a current or former smoker

    B. Is 55–74 years old

    C. Has a 10–20 pack-year history

    D. Has a 30 pack-year history but no signs or symptoms of lung cancer 

    June 14, 2018
    Immunotherapy Plus Chemo Improves Survival in Metastatic Lung Cancer
    Immunotherapy

    Immunotherapy Plus Chemo Improves Survival in Metastatic Lung Cancer

    Combining pembrolizumab and platinum chemotherapy plus pemetrexed doubles survival in patients with nonsquamous non-small cell lung cancer (NSNSCLC) without EGFR or ALK gene mutations, according to the results of a study published in the New England Journal of Medicine.

    June 06, 2018
    ASCO Annual Meeting

    Patients Report More Satisfaction With Multidisciplinary Care Versus Serial Care for Lung Cancer

    Despite the prevalence of multidisciplinary (MD) care for cancer, rigorous studies comparing it to serial care (SC) are lacking. To address the literature gap, researchers explored the use of MD versus SC for lung cancer and presented the findings at the 2018 American Society of Clinical Oncology Annual Meeting.

    June 02, 2018
    ONS Congress

    Tips for Creating a Multidisciplinary Research Team Focused on Symptom Management

    Catherine Bender, PhD, RN, FAAN, of the University of Pittsburgh, and Amy Hoffman, PhD, RN, of Michigan State University, shared their experiences in building interdisciplinary research teams to assess symptom management during a session at the 43rd Annual Congress in Washington, DC.

    May 19, 2018
    ONS Congress

    Immunotherapy Opens New Frontiers in Lung Cancer Care

    The development of targeted therapies brought new progress to lung cancer treatment and research in the past 20 years, and new options will continue to be available in the future. Roy Herbst, MD, PhD, director of thoracic oncology research program at the Yale Comprehensive Cancer Center at Yale School of Medicine in New Haven, CT, spoke at the 43rd Annual Congress in Washington, DC, on new standards of care for non-small cell lung cancer (NSCLC), immunotherapy for NSCLC, and development of rational drug combinations using biomarkers.

    May 19, 2018
    Regular Exercise May Improve Outcomes in Patients With Lung Cancer
    Research

    Regular Exercise May Improve Outcomes in Patients With Lung Cancer

    In addition to lowering cancer risk, regular exercise before lung cancer surgery may improve postoperative outcomes, especially in lung cancer, according to the results of a literature review published in the British Journal of Sports Medicine.

    May 02, 2018
    Study Reports Overall U.S. Cancer Incidence Trends
    Cancer research

    Study Reports Overall U.S. Cancer Incidence Trends

    Overall cancer incidence rates continue to fall for men and remain stable for women, according to the Cancer Statistics, 2018, report published in CA: A Cancer Journal for Clinicians. 

    March 14, 2018
    american tobacco use
    Health Policy

    Despite Awareness, 20% of American Adults Use Tobacco Products

    It’s been 20 years since a panel of tobacco executives stood before Congress and admitted that their products were both addictive and linked to cancer. Since then, Americans have shifted their understanding about the use of tobacco products in ways not previously thought possible. These changes in perception and behavior are due in part to the public health initiatives and anti-tobacco campaigns of the last two decades.

    December 08, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Marketing Approval to FoundationOne CDx In Vitro Diagnostic

    On November 30, 2017, the U.S. Food and Drug Administration granted marketing approval to the FoundationOne CDx, a next generation sequencing based in vitro diagnostic to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.

    November 30, 2017
    Study Finds How Smoking Contributes to Epigenetics of Lung Cancer
    Lung Cancer

    Study Finds How Smoking Contributes to Epigenetics of Lung Cancer

    Although cigarette use has long been linked to lung cancer, scientists have not understood how the earliest changes in lung cells developed. In a study published in Cancer Cell, researchers showed how cigarette smoke sensitized airway cells to genetic mutations that are known to cause lung cancers.

    November 22, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Alectinib for ALK-Positive, Advanced, Metastatic NSCLC

    On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to alectinib (Alecensa) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.

    November 06, 2017
    Recent Drug Approvals Offer New Options for Non-Small Cell Lung Cancer, Genitourinary Cancers, and More
    Treatments

    Recent Drug Approvals Offer New Options for Non-Small Cell Lung Cancer, Genitourinary Cancers, and More

    Cancer treatment options continue to multiply as 2017 continues, with the U.S. Food and Drug Administration (FDA) granting multiple new drug approvals and broadening indications for others. Oncology clinicians and nurses are challenged with staying abreast of treatment option expansions and navigating the dynamic field of cancer treatment to effectively navigate their patients through the treatment trajectory, educating on vital points relative to treatment, minimizing morbidity and mortality, and optimizing quality of life. Following is an overview of the latest approvals for the second quarter of 2017.

    September 27, 2017
    Dendritic Cell Vaccine
    Immunotherapy

    Dendritic Cell Vaccine Uses Immune System to Fight NSCLC

    A new study testing a dendritic cell vaccine for the first time in humans to treat non-small cell lung cancer (NSCLC) has shown that it successfully amplifies the immune system to boost the effectiveness of anti-PD-1 immunotherapies against the cancer. The findings were published in Clinical Cancer Research.

    September 20, 2017
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲